Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents
| Autor: | M-P Gourin, François Dreyfus, J Delaunay, O. Beyne-Rauzy, Raphael Itzykson, C Ravoet, L. Aljassem, A. Ferrant, Norbert Vey, Lionel Ades, Pierre Fenaux, Rosa Sapena, V Coiteux, S. Cheze, A. Stamatoullas, B. Choufi, M Escoffre-barbe, Charikleia Kelaidi, Sophie Park, Emmanuel Raffoux |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Lower risk Trisomy 8 Refractory Recurrence hemic and lymphatic diseases Internal medicine Medicine Humans Cumulative incidence business.industry Myelodysplastic syndromes Myeloid leukemia Anemia Hematology medicine.disease Surgery Treatment Outcome Oncology Myelodysplastic Syndromes Cohort Hematinics Erythropoiesis Chromosomes Human Pair 5 Female business |
| Zdroj: | Leukemia. 27(6) |
| ISSN: | 1476-5551 |
| Popis: | A large proportion of lower-risk myelodysplastic syndromes (MDS) respond to erythropoiesis-stimulating agents (ESA), but most responses are transient. We updated a previously reported cohort of lower-risk MDS patients treated with ESA and analyzed outcomes after ESA failure. In 120 patients with primary resistance and 66 patients with relapse after an initial response to ESA, the 5-year cumulative incidence of acute myeloid leukemia (AML) after failure was 18.9% and 11.6%, respectively (P=0.20). Median overall survival (OS) after failure was 40.1 and 44.9 months (P=0.35), respectively. We further categorized patients as 'early failures' (including resistance and relapse after |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|